FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2560419496> ?p ?o ?g. }

• W2560419496 abstract "Abstract Strategies the outcome for AML patients involve the use of new agents with reduced toxicity. Gemtuzumab ozogamicin (GO) is an immunoconjugate that has shown controversial activity in AML. It is composed of a humanized anti-CD33 antibody linked to the potent antitumor antibiotic calicheamicin. This agent provides a novel method of drug delivery by using the monoclonal antibody to target CD33+ leukemic cells without many of the systemic toxicities associated with traditional chemotherapeutic agents. The therapeutic activity and toxicity profile of GO were assessed in 30 patients from our institution (12 males, 18 females), aged 18 to 74 (median, 63 years), with AML who were either in first (n = 5), second (n = 10), third (n = 12), or fourth line (n = 3) of therapy. The drug was administered either at the dose of 6 mg/m2 as a single 2-hour IV infusion on days 1 and 15 (n = 6) or at the dose of 3 mg/m2 on days 1, 4 and 7 (n = 24). The overall CR/CRp proportion after GO was 30% (95% CI, 15% – 49%). The CR/CRp proportions were 20%, 30%, and 33% for patients treated in first, second, or further therapeutic line respectively. There was no influence of cytogenetics, antecedents of myelodysplasia, or previous treatment by stem cell transplantation on CR/CRp proportions. Only age (54% in patients < 60 years vs 12% for those ≥ 60 years; p = 0.01) and surprisingly gender (50% in females vs none in males; p = 0.003) influenced CR/CRp proportions. Of the 30 patients, 20 (67%) received the scheduled injections. Reasons for not administering the full dose were progressive disease and drug-induced toxicity. Myelosuppression was universally observed during treatment (93%). Additional severe toxicities that occurred during therapy were: febrile neutropenia and infections (63%), intolerance (10%), liver toxicity (10%). Veno-occlusive disease was observed in one patient. Salvage or consolidation treatment by chemotherapy or donor lymphocyte infusion (in previously transplanted patients) was administered to 16 patients only. CR/CRp proportion raises to 43% after salvage therapy. The duration of previous CR appeared then as of prognostic value for CR achievement (17% for previous CR < 6 months vs 64% for CR ≥ 6 months; p = 0.02). Three patients received allogeneic stem cell transplantation as postremission therapy. Eight of the 13 patients who achieved CR relapsed (median, 4.1 months). After relapse, 3 patients were retreated with GO, of which 2 achieved CR again. The median DFS time was 3 months with a 6–month DFS at 22%. The median overall survival time for all patients was 6.8 months with a 6-month and a 1-year survival rates of 57% and 35% respectively. Age (p = 0.01), duration of previous CR (p = 0.002), and achievement of CR after GO therapy (p = 0.01) were the only factors that impact on outcome in terms of OS. These results suggest that the option of single agent GO therapy is viable in this patient population. Although only observed in 30%, responses were present regardless of the karyotype. However, responses were short warranting additional studies using GO in combination with other drugs or chemotherapy." @default.
• W2560419496 created "2016-12-16" @default.
• W2560419496 creator A5004009582 @default.
• W2560419496 creator A5007908757 @default.
• W2560419496 creator A5019277748 @default.
• W2560419496 creator A5028508696 @default.
• W2560419496 creator A5052966035 @default.
• W2560419496 creator A5068217025 @default.
• W2560419496 creator A5070792872 @default.
• W2560419496 creator A5072027146 @default.
• W2560419496 creator A5072721892 @default.
• W2560419496 creator A5082189560 @default.
• W2560419496 creator A5087870886 @default.
• W2560419496 date "2005-11-16" @default.
• W2560419496 modified "2023-10-14" @default.
• W2560419496 title "Gemtuzumab Ozogamicin (Mylotarg®) as Single Agent Treatment for Adult Patients with Acute Myeloid Leukemia (AML)." @default.
• W2560419496 doi "https://doi.org/10.1182/blood.v106.11.4598.4598" @default.
• W2560419496 hasPublicationYear "2005" @default.
• W2560419496 type Work @default.
• W2560419496 sameAs 2560419496 @default.
• W2560419496 citedByCount "2" @default.
• W2560419496 crossrefType "journal-article" @default.
• W2560419496 hasAuthorship W2560419496A5004009582 @default.
• W2560419496 hasAuthorship W2560419496A5007908757 @default.
• W2560419496 hasAuthorship W2560419496A5019277748 @default.
• W2560419496 hasAuthorship W2560419496A5028508696 @default.
• W2560419496 hasAuthorship W2560419496A5052966035 @default.
• W2560419496 hasAuthorship W2560419496A5068217025 @default.
• W2560419496 hasAuthorship W2560419496A5070792872 @default.
• W2560419496 hasAuthorship W2560419496A5072027146 @default.
• W2560419496 hasAuthorship W2560419496A5072721892 @default.
• W2560419496 hasAuthorship W2560419496A5082189560 @default.
• W2560419496 hasAuthorship W2560419496A5087870886 @default.
• W2560419496 hasConcept C10205521 @default.
• W2560419496 hasConcept C126322002 @default.
• W2560419496 hasConcept C143998085 @default.
• W2560419496 hasConcept C159654299 @default.
• W2560419496 hasConcept C176290653 @default.
• W2560419496 hasConcept C203014093 @default.
• W2560419496 hasConcept C2776694085 @default.
• W2560419496 hasConcept C2776755627 @default.
• W2560419496 hasConcept C2778245361 @default.
• W2560419496 hasConcept C2778461978 @default.
• W2560419496 hasConcept C2778556491 @default.
• W2560419496 hasConcept C2778623314 @default.
• W2560419496 hasConcept C2778729363 @default.
• W2560419496 hasConcept C2779263901 @default.
• W2560419496 hasConcept C28328180 @default.
• W2560419496 hasConcept C2911091166 @default.
• W2560419496 hasConcept C29730261 @default.
• W2560419496 hasConcept C542903549 @default.
• W2560419496 hasConcept C54355233 @default.
• W2560419496 hasConcept C71924100 @default.
• W2560419496 hasConcept C86803240 @default.
• W2560419496 hasConcept C90924648 @default.
• W2560419496 hasConcept C98274493 @default.
• W2560419496 hasConceptScore W2560419496C10205521 @default.
• W2560419496 hasConceptScore W2560419496C126322002 @default.
• W2560419496 hasConceptScore W2560419496C143998085 @default.
• W2560419496 hasConceptScore W2560419496C159654299 @default.
• W2560419496 hasConceptScore W2560419496C176290653 @default.
• W2560419496 hasConceptScore W2560419496C203014093 @default.
• W2560419496 hasConceptScore W2560419496C2776694085 @default.
• W2560419496 hasConceptScore W2560419496C2776755627 @default.
• W2560419496 hasConceptScore W2560419496C2778245361 @default.
• W2560419496 hasConceptScore W2560419496C2778461978 @default.
• W2560419496 hasConceptScore W2560419496C2778556491 @default.
• W2560419496 hasConceptScore W2560419496C2778623314 @default.
• W2560419496 hasConceptScore W2560419496C2778729363 @default.
• W2560419496 hasConceptScore W2560419496C2779263901 @default.
• W2560419496 hasConceptScore W2560419496C28328180 @default.
• W2560419496 hasConceptScore W2560419496C2911091166 @default.
• W2560419496 hasConceptScore W2560419496C29730261 @default.
• W2560419496 hasConceptScore W2560419496C542903549 @default.
• W2560419496 hasConceptScore W2560419496C54355233 @default.
• W2560419496 hasConceptScore W2560419496C71924100 @default.
• W2560419496 hasConceptScore W2560419496C86803240 @default.
• W2560419496 hasConceptScore W2560419496C90924648 @default.
• W2560419496 hasConceptScore W2560419496C98274493 @default.
• W2560419496 hasLocation W25604194961 @default.
• W2560419496 hasOpenAccess W2560419496 @default.
• W2560419496 hasPrimaryLocation W25604194961 @default.
• W2560419496 hasRelatedWork W154275580 @default.
• W2560419496 hasRelatedWork W2007433984 @default.
• W2560419496 hasRelatedWork W2025545798 @default.
• W2560419496 hasRelatedWork W2069196662 @default.
• W2560419496 hasRelatedWork W2081685992 @default.
• W2560419496 hasRelatedWork W2466416244 @default.
• W2560419496 hasRelatedWork W2490023968 @default.
• W2560419496 hasRelatedWork W2741979498 @default.
• W2560419496 hasRelatedWork W2763956699 @default.
• W2560419496 hasRelatedWork W2884323144 @default.
• W2560419496 isParatext "false" @default.
• W2560419496 isRetracted "false" @default.
• W2560419496 magId "2560419496" @default.
• W2560419496 workType "article" @default.